ArticleBiology2022
Evaluation of the BioFire FilmArray Pneumonia Panel Plus to the Conventional Diagnostic Methods in Determining the Microbiological Etiology of Hospital-Acquired Pneumonia.
Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Cumulative respiratory pathogen detection burden by multiplex PCR is associated with mortality in a TB-enriched ICU cohort.Microbiology spectrum · 2026Article
- Etiological characterization of acute respiratory tract infections and associated co-infections using Biofire respiratory 2.1 Plus panel.BMC infectious diseases · 2026Article
- Evolving Approaches to Bacterial Identification: A Review of Classical and Modern Techniques.International journal of molecular sciences · 2026Review
- Faster Diagnosis of Suspected Lower Respiratory Tract Infections: Single-Center Evidence from BIOFIRE FilmArrayDiagnostics (Basel, Switzerland) · 2026Article
- Multiplex PCR for lower respiratory tract infection diagnosis in ICU and non-ICU settings: enhancing diagnostic stewardship in Indian tertiary care.Iranian journal of microbiology · 2025Article
- Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study.Microbiology spectrum · 2025Article
- Role of Respiratory Viruses in Severe Acute Respiratory Failure.Journal of clinical medicine · 2025Review
- Epidemiology and prediction of non-targeted bacteria by the filmarray pneumonia plus panel in culture-positive ventilator-associated pneumonia: a retrospective multicentre analysis.Annals of intensive care · 2025Article
- Detection of clinically relevant Candida species from positive blood cultures using a novel sample-to-answer molecular assay.Scientific reports · 2025Article
- Assessment of a rapid diagnostic test based on loop-mediated isothermal amplification (LAMP) to identify the most frequent pathogens causing hospital-acquired pneumonia.Frontiers in cellular and infection microbiology · 2025Article
- Combinatorial biosynthesis of novel aminoglycoside antibiotics via pathway engineering.AMB Express · 2024Review
- Rapid Molecular Diagnostics of Pneumonia Caused by Gram-Negative Bacteria: A Clinician's Review.Antibiotics (Basel, Switzerland) · 2024Review
- Practice Versus Potential: The Impact of the BioFire FilmArray Pneumonia Panel on Antibiotic Use in Children.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Real-life Assessment of BioFire FilmArray Pneumonia Panel in Adults Hospitalized With Respiratory Illness.The Journal of infectious diseases · 2024Article
- Effectiveness of Pre-Transplant Screening for High-Priority Multidrug-Resistant Pathogens on Pre-Engraftment Infections After Hematopoietic Stem Cell Transplantation.Infection and drug resistance · 2024Article
- Evaluation of the BioFire® FilmArray® PneumoniaPolish journal of microbiology · 2023Article
- Supporting Clinical Decisions with Rapid Molecular Diagnostic Pneumonia Panel in Pediatric Intensive Care Unit: Single Center Experience in Turkiye.Microorganisms · 2023Article
- Diagnostic accuracy of the BioFire® FilmArray® pneumonia panel in COVID-19 patients with ventilator-associated pneumonia.BMC infectious diseases · 2023Article
- Evaluation of the BioFireDiagnostics (Basel, Switzerland) · 2023Article
- Clinical impact of a multiplex rapid diagnostic pneumonia panel in critically ill patients.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Hospital-acquired pneumonia (HAP) is a substantial public health issue that is associated with high mortality rates and is complicated by an arsenal of microbial etiologies, expressing multidrug-resistant phenotypes, rendering relatively limited therapeutic options. BioFire FilmArray Pneumonia Panel plus (BFPP) is a simple multiplexed PCR system that integrates sample preparation, nucleic acid extraction, amplification, and analysis of microbial etiology, with a turnaround time of about one hour. In comparison to standard culture methods, BFPP is simpler, easier to perform, and can simultaneously detect the most common pathogens involved in lower respiratory tract infections (34 targets). Accordingly, we evaluated the diagnostic performance of the multiplexed BFPP for the rapid detection of 27 clinically relevant respiratory pathogens and 7 genetic markers among 50 HAP cases admitted to the intensive care unit (ICU), who submitted mini-bronchoalveolar (mBAL) specimens. In comparison to standard culture methods, BFPP showed an overall sensitivity of 100% [95% CI; 90-100] and overall specificity of 90% [95% CI; 87.4-92.5] among all the tested bacterial targets. BFPP identified 11 viral targets (22%) among the tested specimens. The BFPP semi-quantitative analysis showed a concordance rate of 47.4% among positive culture specimens. For the investigation of the antibiotic resistance genes, BFPP showed a positive percent agreement (PPA), a negative percent agreement (NPA), and an overall percent agreement (OPA), reaching 97% [95% CI; 90-100], 95% [95% CI; 91.5-97], and 95% [95% CI; 93-97], respectively, with standard antibiotic sensitivity testing. In conclusion, BFPP has the potential to enhance the rapid microbiological diagnosis of HAP cases, and could aid in tailoring appropriate antibiotic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.